This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.
Males and/or females over age 18
Histologically and/or cytologically documented local advanced or recurrent or metastatic malignancies
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Expected survival >3 months.
Any remaining AEs > grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.
Pregnant or nursing women or women/men who are ready to give birth
Symptomatic central nervous system metastasis.
Allergy to other antibody drugs or any excipients in the study drugs.